RxDoctor Payments Data

Dhruv Agneshwar, MD

Obstetrics & Gynecology · Johnson City, NYNPI 1417922790

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 40.0% of the total. Reporting peaked in 2019 at $397 and has fallen 87.7% since, to $49 in 2025.

$797in general payments, 2019–2025

Across 46 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$319
  • Novo Nordisk$99
  • Therapeuticsmd, Inc.$64
  • Medtronic$54
  • Pfizer$47
  • Axonics, Inc.$35
  • plus $180 from 8 others
$410,906in research payments, 2019–2025

Across 184 payments — averaging $2233.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$210K
  • Pfizer$201K

What the payments were for

  • Food & beverage$78298%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$797 in reported general payments places this provider in the 65th percentile of 2,673 obstetrics & gynecology providers in New York.

See all obstetrics & gynecology providers in New York

Medicare billing

Part B allowed, 2024
$24,412
Medicare patients
110
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol38$2,299

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →